The Habit Formation trial of behavioral economic interventions to improve statin use and reduce the risk of cardiovascular disease: Rationale, design and methodologies.


Journal

Clinical trials (London, England)
ISSN: 1740-7753
Titre abrégé: Clin Trials
Pays: England
ID NLM: 101197451

Informations de publication

Date de publication:
08 2019
Historique:
pubmed: 1 6 2019
medline: 4 9 2020
entrez: 1 6 2019
Statut: ppublish

Résumé

Low adherence to statin (HMG-CoA reductase inhibitors) medication is common. Here, we report on the design and implementation of the Habit Formation trial. This clinical trial assessed whether the interventions, based on principles from behavioral economics, might improve statin adherence and lipid control in at-risk populations. We describe the rationale and methods for the trial, recruitment, conduct and follow-up. We also report on several barriers we encountered with recruitment and conduct of the trial, solutions we devised and efforts we will make to assess their impact on our study. Habit Formation is a four-arm randomized controlled trial. Recruitment of 805 participants at elevated risk of atherosclerotic cardiovascular disease with evidence of sub-optimal statin adherence and low-density lipoprotein (LDL) control is complete. Initially, we recruited from large employers (Employers) and a national health insurance company (Insurers) using mailed letters; individuals with a statin Medication Possession Ratio less than 80% were invited to participate. Respondents were enrolled if a laboratory measurement of low-density lipoprotein was >130 mg/dL. Subsequently, we recruited participants from the Penn Medicine Health System; individuals with usual-care low-density lipoprotein of >100 mg/dL in the electronic medical record were recruited using phone, text, email, and regular mail. Eligible participants self-reported incomplete medication adherence. During a 6-month intervention period, all participants received a wireless-enabled pill bottle for their statins and daily reminder messages to take their medication. Principles of behavioral economics were used to design three financial incentives, specifically a Simple Daily Sweepstakes rewarding daily medication adherence, a Deadline Sweepstakes where participants received either a full or reduced incentive depending on whether they took their medication before or after a daily reminder or Sweepstakes Plus Deposit Contract with incentives divided between daily sweepstakes and a monthly deposit. Six months post-incentives, we compared the primary outcome, mean change from baseline low-density lipoprotein, across arms. Health system recruitment yielded substantially better enrollment and was cost-efficient. Despite unexpected systematic failure and/or poor availability of two wireless pill bottles, we achieved enrollment targets and implemented the interventions. For new trials, we will routinely monitor device function and have contingency plans in the event of systemic failure. Interventions used in the Habit Formation trial could be translated into clinical practice. Within a large health system, successful recruitment depended on identification of eligible individuals through their electronic medical record, along with flexible ways of contacting these individuals. Challenges with device failure were manageable. The study will add to our understanding of optimally structuring and implementing incentives to motivate durable behavior change.

Sections du résumé

BACKGROUND
Low adherence to statin (HMG-CoA reductase inhibitors) medication is common. Here, we report on the design and implementation of the Habit Formation trial. This clinical trial assessed whether the interventions, based on principles from behavioral economics, might improve statin adherence and lipid control in at-risk populations. We describe the rationale and methods for the trial, recruitment, conduct and follow-up. We also report on several barriers we encountered with recruitment and conduct of the trial, solutions we devised and efforts we will make to assess their impact on our study.
METHODS
Habit Formation is a four-arm randomized controlled trial. Recruitment of 805 participants at elevated risk of atherosclerotic cardiovascular disease with evidence of sub-optimal statin adherence and low-density lipoprotein (LDL) control is complete. Initially, we recruited from large employers (Employers) and a national health insurance company (Insurers) using mailed letters; individuals with a statin Medication Possession Ratio less than 80% were invited to participate. Respondents were enrolled if a laboratory measurement of low-density lipoprotein was >130 mg/dL. Subsequently, we recruited participants from the Penn Medicine Health System; individuals with usual-care low-density lipoprotein of >100 mg/dL in the electronic medical record were recruited using phone, text, email, and regular mail. Eligible participants self-reported incomplete medication adherence. During a 6-month intervention period, all participants received a wireless-enabled pill bottle for their statins and daily reminder messages to take their medication. Principles of behavioral economics were used to design three financial incentives, specifically a Simple Daily Sweepstakes rewarding daily medication adherence, a Deadline Sweepstakes where participants received either a full or reduced incentive depending on whether they took their medication before or after a daily reminder or Sweepstakes Plus Deposit Contract with incentives divided between daily sweepstakes and a monthly deposit. Six months post-incentives, we compared the primary outcome, mean change from baseline low-density lipoprotein, across arms.
RESULTS AND LESSONS LEARNED
Health system recruitment yielded substantially better enrollment and was cost-efficient. Despite unexpected systematic failure and/or poor availability of two wireless pill bottles, we achieved enrollment targets and implemented the interventions. For new trials, we will routinely monitor device function and have contingency plans in the event of systemic failure.
CONCLUSION
Interventions used in the Habit Formation trial could be translated into clinical practice. Within a large health system, successful recruitment depended on identification of eligible individuals through their electronic medical record, along with flexible ways of contacting these individuals. Challenges with device failure were manageable. The study will add to our understanding of optimally structuring and implementing incentives to motivate durable behavior change.

Identifiants

pubmed: 31148473
doi: 10.1177/1740774519846852
pmc: PMC6663645
mid: NIHMS1526612
doi:

Substances chimiques

Hydroxymethylglutaryl-CoA Reductase Inhibitors 0
Lipoproteins, LDL 0

Banques de données

ClinicalTrials.gov
['NCT01798784']

Types de publication

Clinical Trial Protocol Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

399-409

Subventions

Organisme : NIA NIH HHS
ID : R01 AG043844
Pays : United States

Références

Clin Chem. 2002 Feb;48(2):236-54
pubmed: 11805004
JAMA. 2007 Nov 28;298(20):2415-7
pubmed: 18042920
Am Heart J. 2008 Apr;155(4):772-9
pubmed: 18371492
Am J Public Health. 1987 Nov;77(11):1417-26
pubmed: 3661794
N Engl J Med. 2007 Sep 27;357(13):1340-4
pubmed: 17898105
BMJ. 2001 Nov 10;323(7321):1123-4
pubmed: 11701584
N Engl J Med. 2015 May 28;372(22):2108-17
pubmed: 25970009
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45
pubmed: 24222016
JAMA. 2015 Nov 10;314(18):1926-35
pubmed: 26547464
Lancet. 2017 Mar 18;389(10074):1097
pubmed: 28322813
Lancet. 2005 Oct 8;366(9493):1267-78
pubmed: 16214597
N Engl J Med. 2018 Jan 11;378(2):101-103
pubmed: 29281504
Cogn Psychol. 1999 Feb;38(1):129-66
pubmed: 10090801
JAMA. 2002 Jul 24-31;288(4):462-7
pubmed: 12132976
JAMA Cardiol. 2017 Aug 1;2(8):890-895
pubmed: 28423147
Am J Med. 2009 Oct;122(10):961.e7-13
pubmed: 19560749
Emerg Infect Dis. 2018 Oct;24(10):1806-1815
pubmed: 30226154
Lancet. 1994 Nov 19;344(8934):1383-9
pubmed: 7968073
Pediatr Blood Cancer. 2014 Jun;61(6):1068-73
pubmed: 24436121
Circ Cardiovasc Qual Outcomes. 2017 Oct;10(10):
pubmed: 29021332
JAMA Intern Med. 2017 May 1;177(5):624-631
pubmed: 28241271
Lancet. 2007 Nov 24;370(9601):1781-90
pubmed: 17559928
Arch Intern Med. 2006 Sep 25;166(17):1836-41
pubmed: 17000939
Circulation. 2017 Nov 14;136(20):1878-1891
pubmed: 28877913
Lancet. 2010 Nov 13;376(9753):1670-81
pubmed: 21067804
N Engl J Med. 2004 Apr 8;350(15):1495-504
pubmed: 15007110

Auteurs

Mary E Putt (ME)

1 Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Peter P Reese (PP)

1 Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
2 Renal Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
8 The Leonard Davis Institute of Health Economics (LDI), University of Pennsylvania, Philadelphia, PA, USA.

Kevin G Volpp (KG)

3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.
4 Corporal Michael Crescenz VA Medical Center, Philadelphia, PA, USA.
8 The Leonard Davis Institute of Health Economics (LDI), University of Pennsylvania, Philadelphia, PA, USA.

Louise B Russell (LB)

3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.
8 The Leonard Davis Institute of Health Economics (LDI), University of Pennsylvania, Philadelphia, PA, USA.

George Loewenstein (G)

5 Department of Social and Decision Sciences, Carnegie Mellon University, Pittsburgh, PA, USA.

Jiali Yan (J)

3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.

David Pagnotti (D)

3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.

Ryan McGilloway (R)

3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.

Troyen Brennen (T)

6 Department of Health Policy & Management, T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.

Darra Finnerty (D)

3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.

Karen Hoffer (K)

3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.

Sakshum Chadha (S)

3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.

Iwan Barankay (I)

7 Department of Management and Department of Business Economics and Public Policy, The Wharton School, University of Pennsylvania, Philadelphia, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH